Ayurcann Holdings Corp. · OTC:AYURF
Ayurcann — Investor Presentation (May 2021)
22 slides from Ayurcann's investor presentation, May 2021
Slide 1: Ayurcann Holdings Corp. Investor Presentation May 2021
Ayurcann Holdings Corp. (CSE: AYUR) Investor Presentation May 2021 Toll Processing & White Label Manufacturing Solutions For Canadian Licensed Producers
Slide 2: Ayurcann at a Glance
Ayurcann at a Glance EBITDA And Cash Flow Positive High-Margin Branded Leading Product Cannabis 2.0 offerings Product Manufacturer Very Low Debt Opex Free = Massive Operating Leverage 20+ Clients In First 6 Month High Gross Of Operations Margins Asset Light = Outstanding low Capex 2 Investor Present
Slide 3: Market Opportunity
Market Opportunity Rapidly growing Cannabis 2.0 market segment CANADIAN CANNABIS MARKET * CANNABIS 2.0 SEGMENT SALES GROWTH** Capsules Tinctures Capsules Tinctures & Sublinguals & Sublinguals $10.1B 10% Vape Pens 6% Vape Pens 2025 3.9% 18% Edibles Edibles 1% 9% Topicals Topicals 0% ** 1% ~3x $3.1B 2
Slide 4: Market Opportunity: Moving Away From Vertical Integration
Market Opportunity As the cannabis market matures, it moves away from vertical integration As the industry matures, companies specialize and develop competitive advantages in certain segments Service providers develop expertise of the value chain (cultivation, and utilize economies of scale manufact
Slide 5: The Value Chain
The Value Chain Me dic a l Branding Recrea tion Ayurcann is a leading al post harvest solution provider Packaging with a focus on providing and creating custom processes Fulfillment and pharma grade Products Product for the adult use and medical d Manufacturing nn e cannabis industriy in Canada. ca
Slide 6: Milestones & Action Plan
Milestones & Action Plan Unparalleled execution & capital deployment efficiency 2018 2019 2020 2021 Q1. Q2 - Q4. Q1. Q2 - Q4. So far... • Standard Processing • Over $2,500,000 • Submission of 40 SKUs • Launch of XPLOR • Submitted Health • Health Canada License Granted in Revenue* to OCS and HC brand
Slide 7: Key Success Factors
Key Success Factors Simple formula: top services and products, priced competitively (yet profitably…) SERVICES TO LPS MEDICAL LINE OPERATIONAL AND AND BRANDS: OF PRODUCTS FINANCIAL EXCELLENCE • Leveraging efficient • Sales license received • Over $[2.5mm] of revenue technology and infrastructure Jan
Slide 8: Our Offering To LPs and Brands
Our Offering To LPs and Brands EXTRACTION & BULK OIL WHITE LABEL REFINEMENT SALES MANUFACTURING 8 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 9: Extraction & Refinement
Extraction & Refinement • Processed Over 16,000kgs of Biomass to Date • Ethanol extraction specialists • Low cost and high volume production capabilities • Fast and flexible production 9,308 kg Biomass extracted in 2020 0 5% +2 4,530 kg 6% 2,430 kg +18 9% 380 kg +63 Q1 Q2 Q3 Q4 9 Investor Presentati
Slide 10: Bulk Oil Sales
Bulk Oil Sales • Secured over 10,000 kg of biomass below market price. • Monthly inventory availability of over 300kg of distillate • Inventory to supply leading licence producers to support Edibles, Topicals & Vape Production • Quality supply CBD Crude / Distillate / Isolate THC Crude & Distillate
Slide 11: White Label Manufacturing
White Label Manufacturing In-House Developed IP Formulation 19 Product offering (SKUs) in 2020 10 3 0 Q1 Q2 Q3 Q4 11 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 12: Medical Line of Products
Medical Line of Products Tincture Vape Pens Topicals 12 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 13: Brands: Strategic Partnerships with Industry Leaders
Brands Strategic Partnerships with Industry Leaders
Slide 14: Financial Highlights
Financial Highlights $1.59 Revenue growth Client growth 2020 20 2020 ($MM) 17 18 % 82 +1 $0.87 12 $0.74 10 7 6 2 Q2 - 2020 Q3 - 2020 Q4 - 2020 Q2 Q3 Q4 14 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 15: Competitive Landscape
Competitive Landscape Attractive Valuation Relative to Peer Group Current Annual 200,000 kg 100,000 kg 300,OOO kg 425,OOO kg 100,000 kg Extraction Capacity Annual Extraction 300,000 kg 100,000 kg 575,000 kg 425,OOO kg 100,000 kg Capacity at Full Expansion Greater Toronto Greater Canadian Facility Ar
Slide 16: Capital Structure
Capital Structure Proforma Capitalization - Ayurcann Resulting Issuer - Ayurcann Common Shares 100,973,848 Options * 1,408,734 Warrants ** 16,919,469 Total - Fully Diluted 119,302,051 16 Investor Presentation. © 2021 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 17: Management and Directors
Management and Directors Igal Sudman Roman Buzaker Jaspreet Bhatia Raj Virk CEO and Co-founder, Director President, COO and Co-founder, Director Quality Control Manager Quality & Compliance Manager Mr. Sudman is a business development Mr. Buzaker is a corporate strategist Mrs. Bhatia is a Quality Co
Slide 18: Directors
Directors Alison Gordon David Hackett Maor Shayit Director Director Director A veteran of the cannabis industry, Alison has Mr. Hackett brings more than 20 years of financial Mr. Shayit is a seasoned and ambitious operations worked in all verticals of this emerging market. and management leadership.
Slide 19: Advisory Board
Advisory Board Michael Ash Barry Katzman Trina Fraser Michael is the current CEO of Juno OTC Mr. Katzman is an accomplished senior executive Trina is a partner at Brazeau Seller Law and head Pharmaceuticals, an innovative private label supplier and entrepreneur with a strong background in both of BS
Slide 20: Advisory Board
Advisory Board Iris Bincovich Casey Hiltemann Ben Feferman Mrs. Iris Bincovich is the CEO of Innocan Pharma Casey Hiltemann is the Founder and CEO of Budtenders Ben is the CEO of Amuka Esports, one of Canada’s and an experienced C-level executive in healthcare Associate, an inclusive network working
Slide 21: Disclaimer
Disclaimer General right of action for rescission is exercisable not later than 180 days from the date on which payment is made for the securities. If a purchaser elects to exercise the right The information contained in this presentation has been prepared by Ayurcann Inc. (“Ayurcann”) in connection
Slide 22: Thank You!
Thank You! Contact Us Igal Sudman CEO and Co-founder 905.492.3322 [email protected]